SomaLogic
Closed (deSPAC)Profile in progress
- What it is
- SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives
- What it’s doing now
- Merging with CM Life Sciences II Inc. (SLGC) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
The business, per its filings
SEC primarySomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter. SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory. Non-GAAP Financial Measures We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results used by management to evaluate and run the business, as well as, for financial planning purposes. Our non-GAAP financial measure, Adjusted EBITDA, provides an additional tool for investors to use in comparing our financial performance over multiple periods. Adjusted EBITDA is a key performance measure that our management uses to assess its operating performance. Adjusted EBITDA facilitates internal comparisons of our operating performance on a more consistent basis, and we use this measure for business planning, forecasting, and decision-making. We believe that Adjusted EBITDA enhances an investor’s understanding of our financial performance as it is useful in assessing our operating performance from period-to-period by excluding certain items that we believ
What the company says about itself
Web research — not auditedSomaLogic provides high-throughput proteomics services and solutions using aptamer-based technology (SOMAmer Reagents) for discovery, validation, and development in therapeutic areas such as diabetes, cancer, and neurology. They offer fee-for-service, CLIA-certified, CAP-accredited lab services at their U.S. World Headquarters and through a worldwide network of Authorized Sites.
- Markets:
- Proteomics | Biomarker Discovery | Pharmaceutical | Biotechnology | Contract Research Organization | Academic Medical Center
- Products:
- SomaScan Assay | SOMAmer Reagents
[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Combination is expected to provide up to $651 million in cash proceeds for SomaLogic, expanding the cash on its balance sheet to $686 million" [https://ii.cmlifesciencesspac.com/wp-content/uploads/2021/03/SL-CMLS-Announcement-v032921_2.00pm.pdf]
Source: https://somalogic.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
SomaLogic is merging with CM Life Sciences II Inc. (SLGC) currently marked Closed (deSPAC).
| Headline equity value | — |
Structure per SEC accession(s) 0001104659-23-122894. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is SomaLogic going public?
SomaLogic has an approved merger with the SPAC CM Life Sciences II Inc. (SLGC). Deal status: Closed (deSPAC).
Does SomaLogic have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.